MAPT and Alzheimer disease: Currently, the 2024 Alzheimer’s drug development pipeline indicates that there are 164 trials assessing 127 unique drugs for AD and that these trials target various pathological processes, including Aβ, tau, inflammation, neurotransmitter receptors, and synaptic plasticity (Cummings et al., 2024).